Related Experiment Video
Updated: Sep 2, 2025
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
Abstract:
Survival benefit and a manageable safety profile were observed with G47Δ in patients with glioblastoma.
Insights
G47Δ demonstrated survival benefits and a manageable safety profile in glioblastoma patients. This oncolytic virus therapy shows promise for treating this aggressive brain cancer.
Area of Science:
- Neuro-oncology
- Viral Oncology
- Oncolytic Virus Therapy
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Developing novel therapeutic strategies is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of G47Δ in patients with glioblastoma.
- To assess the survival benefit conferred by G47Δ treatment.
Main Methods:
- Clinical trial involving glioblastoma patients treated with G47Δ.
- Monitoring of patient survival and adverse events.
Main Results:
- G47Δ treatment resulted in a survival benefit for glioblastoma patients.
- The safety profile of G47Δ was observed to be manageable.
Conclusions:
- G47Δ shows potential as a therapeutic agent for glioblastoma.
- Further investigation into G47Δ for brain tumor treatment is warranted.
